Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Patients With Brain Metastasis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2003
To verify the number of metastatic brain tumors detected in contrast-enhanced MRI, which is the primary variable, increases after an additional dose of Magnevist (SH L 451A) comparing images after an initial dose (0.1 mmol/kg) with those after an additional dose (0.1 mmol/kg, a total dose of 0.2 mmol/kg) intra-individually in patients with metastatic brain tumors. Safety was also to be assessed.
Epistemonikos ID: 4e0e734ec9d7f58335e812c8585357ec63828962
First added on: May 05, 2024